Hypogonadotropic hypogonadism in subjects with DAX1 mutations
► In humans, mutations in DAX1 cause adrenal hypoplasia congenita and hypogonadotropic hypogonadism. ► Hypogonadotropic hypogonadism involves a combined hypothalamic and pituitary deficiency leading to low LH and FSH. ► Animal studies reveal that DAX1 duplication causes sex reversal whereas loss-of-...
Gespeichert in:
Veröffentlicht in: | Molecular and cellular endocrinology 2011-10, Vol.346 (1), p.65-73 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | ► In humans, mutations in
DAX1 cause adrenal hypoplasia congenita and hypogonadotropic hypogonadism. ► Hypogonadotropic hypogonadism involves a combined hypothalamic and pituitary deficiency leading to low LH and FSH. ► Animal studies reveal that DAX1 duplication causes sex reversal whereas loss-of-function mutations cause testicular and adrenal developmental defects. ► Traditionally known as a repressor of SF-1, DAX1 works with multiple co-activators and co-repressors to control gene expression.
DAX1 (dosage-sensitive sex reversal, adrenal hypoplasia critical region, on chromosome X, gene 1; also known as
NROB1, nuclear receptor subfamily 0, group B, member 1) encodes a nuclear receptor that is expressed in embryonic stem (ES) cells, steroidogenic tissues (gonads, adrenals), the ventromedial hypothalamus (VMH), and pituitary gonadotropes. Humans with
DAX1 mutations develop an X-linked syndrome referred to as adrenal hypoplasia congenita (AHC). These boys typically present in infancy with adrenal failure but later fail to undergo puberty because of hypogonadotropic hypogonadism (HHG). The adrenal failure reflects a developmental abnormality in the transition of the fetal to adult zone, resulting in glucocorticoid and mineralocorticoid deficiency. The etiology of HHG involves a combined and variable deficiency of hypothalamic GnRH secretion and/or pituitary responsiveness to GnRH resulting in low LH, FSH and testosterone. Treatment with exogenous gonadotropins generally does not induce spermatogenesis. Animal models indicate that DAX1 also plays a critical role in testis development and function. As a nuclear receptor, DAX1 has been shown to function as a transcriptional repressor, particularly of pathways regulated by other nuclear receptors, such as steroidogenic factor 1 (SF1). In addition to reproductive tissues, DAX1 is also expressed at high levels in ES cells and plays a role in the maintenance of pluripotentiality. Here we review the clinical manifestations associated with
DAX1 mutations as well as the evolving information about its function based on animal models and
in vitro studies. |
---|---|
ISSN: | 0303-7207 1872-8057 |
DOI: | 10.1016/j.mce.2011.04.017 |